News

Diabetes drug company call for approval

Diabetes drug company Takeda Pharmaceutical Co this week announced that it had applied for approval to market a joint diabetes treatment in the United States. The drug, which combines SYR-332 and blockbuster drug Actos, is available as a single tablet.
Actos, which will lose patent protection in America in 2011, has been a bestseller for Takeda. A spokeswoman for the company, Ayako Iwamuro, reportedly commented: “It is the world’s first drug combining alogliptin (the generic name of SYR-322) and pioglitazone (the generic name of Actos). We see this providing us with a major foothold in coping with the impact of the patent expiry for Actos.”
The earliest that the pharmaceutical company will get a decision on their drug will be in 10 months time.

To Top